PharmaMar initiates solid tumour drug study
PM060184, which is a marine-derived, synthetically-produced compound, had demonstrated strong in vitro and in vivo antitumour activity and a favourable safety profile in preclinical toxicology studies. The trials
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.